In silico binding affinity studies of N-9 substituted 6-(4-(4-propoxyphenyl)piperazin-1-yl)-9H-purine derivatives-Target for P70-S6K1 & PI3K-δ kinases

Ali, 2004, Essential role for the p110delta phosphoinositide 3-kinase in the allergic response, Nature, 431, 1007, 10.1038/nature02991 Anthony, 2014, A phase I trial of LY2584702 tosylate, a p70 S6 kinase inhibitor, in patients with advanced solid tumours, Eur. J. Cancer, 50, 867, 10.1016/j.ejca.2013.11.039 Arun, 2014, 411 Berman, 2008, The Protein Data Bank: a historical perspective, Acta Crystallogr. A, 64, 88, 10.1107/S0108767307035623 Bostner, 2015, S6 kinase signaling: tamoxifen response and prognostic indication in two breast cancer cohorts, Endocr. Relat. Cancer, 22, 331, 10.1530/ERC-14-0513 Christian, 2007, PI3Kδ and PI3Kγ: partners in crime in inflammation in rheumatoid arthritis and beyond?, Nat. Rev. Immunol., 7, 191, 10.1038/nri2036 Chopra, 2014, Novel piperazine-based compounds inhibit microtubule dynamics and sensitize colon cancer cells to tumor necrosis factor-induced apoptosis, J. Biol. Chem., 289, 2978, 10.1074/jbc.M113.499319 Clayton, 2002, A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation, J. Exp. Med., 196, 753, 10.1084/jem.20020805 David, M.A.T., Stuart, T.O., Alun, J.S., Alex, H.C., Rudy, L.M.B., 2016. Phosphoinositide 3-kinase inhibitors, US9227977. Gasteiger, 1980, Iterative partial equalization of orbital electronegativity-a rapid access to atomic charges, Tetrahedron, 36, 3219, 10.1016/0040-4020(80)80168-2 Garrett, 2008, Molecular modeling of proteins, Methods molecular biology, vol. 443 Hans-Joachim, 2004, Fluorine in medicinal chemistry, ChemBioChem, 5, 637, 10.1002/cbic.200301023 Hans, 2012, 187 Harish, 2016, Discovery of a latent calcineurin inhibitory peptide from its autoinhibitory domain by docking, dynamic simulation, and in vitro methods, J. Biomol. Struct. Dyn., 34, 983, 10.1080/07391102.2015.1064829 Harish, 2013, In silico binding affinity study of calcineurin inhibitors to calcineurin and its close associates, Indian. J. Biotechnol., 12, 213 Ipsita, 2012, PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes, Acta Pharmacol. Sin., 33, 1441, 10.1038/aps.2012.72 Irene, 2012, Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment, BMC Med., 10, 1 Ingrid, 2016, The PI3K/AKT pathway as a target for cancer treatment, Annu. Rev. Med., 67, 11, 10.1146/annurev-med-062913-051343 Jerome de, 2016, Molecular docking as a popular tool in drug design, an in silico travel, Adv. Appl. Bioinf. Chem., 9, 1 Khaled, 2013, Docking challenge: protein sampling and molecular docking performance, J. Chem. Inf. Model., 53, 1934, 10.1021/ci400040d Kendall, 2016, Alphavirus protease inhibitors from natural sources: A homology modeling and molecular docking investigation, Comput. Biol. Chem., 64, 163, 10.1016/j.compbiolchem.2016.06.005 Keshwani, 2009, Mechanism of PDK1-catalyzed Thr-229 phosphorylation of the S6K1 protein kinase, J. Biol. Chem., 284, 22611, 10.1074/jbc.M109.032177 Khurum, 2013, Targeting the PI3K-AKT-mTOR signaling network in cancer, Chin. J. Cancer, 32, 253, 10.5732/cjc.013.10057 Kim, 2009, Regulation and localization of ribosomal protein S6 kinase 1 isoforms, Growth Factors, 27, 12, 10.1080/08977190802556986 Laura, 2010, Characterization of PF-4708671, a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1), Biochem. J., 431, 245, 10.1042/BJ20101024 Le, 2003, Paclitaxel induces inactivation of p70 S6 kinase and phosphorylation of Thr421 and Ser424 via multiple signaling pathways in mitosis, Oncogene, 22, 484, 10.1038/sj.onc.1206175 Leena, 2016, 2,4,6-Triaminopyrimidine as a novel hinge binder in a series of PI3Kδ selective inhibitors, J. Med. Chem., 59, 3532, 10.1021/acs.jmedchem.6b00213 Leise, 2000, Cellular function of p70S6K: a role in regulating cell motility, Immunol. Cell Biol., 78, 447, 10.1046/j.1440-1711.2000.00928.x Leonardo, 2015, Molecular docking and structure-based drug design strategies, Molecules, 20, 13384, 10.3390/molecules200713384 Manjunath, 2016, Synthesis of novel N-9 substituted 6-(4-(4-propoxyphenyl)piperazin-1-yl)-9H-purine derivatives as inducers of apoptosis in MCF-7 breast cancer cells, RSC Adv., 6, 15286, 10.1039/C5RA23242B Michael, 2009, Small molecule inhibitors of phosphoinositide 3-Kinase (PI3K) δ and γ, Curr. Top. Med. Chem., 9, 738, 10.2174/156802609789044434 Mohd Sajid, 2013, Design, synthesis, evaluation and thermodynamics of 1-substituted Pyridylimidazo[1,5-a]Pyridine derivatives as cysteine protease inhibitors, PLoS One., 8, e69982, 10.1371/journal.pone.0069982 Mohammad Hassan, 2016, Computer Aided Drug Design: Success and Limitations, Curr. Pharm. Des., 22, 572, 10.2174/1381612822666151125000550 Neel, K.A., Charles, M.B., Owen, J.B., Joerg, B., Lynne, C.B., Diva, S.C., Baili, C., Erick, W.C., Simona, C., Steven, C.D., Larisa, D., Maurizio, F., Ping, H., Vasu, J., Richard, G.K., Moon, H.K., Rhett, R.K., Donna, T.L., Morrison, B.M., John, M.N., Jason, J.P., Kenneth, D.R., Tsze, H.T., Amy, L.T., Yong, W., Wei, X., 2011. Kinase modulators and methods of use. US8076338. Patrick, K., 2016. Inhibitors of PI3K-delta and methods of their use and manufacture. US9346807. Poonam, 2007, The role of fluorine in medicinal chemistry, J. Enzyme Inhib. Med. Chem., 22, 527, 10.1080/14756360701425014 Rommel, 2007, PI3K delta and PI3K gamma: partners in crime in inflammation in rheumatoid arthritis and beyond?, Nat. Rev. Immunol., 7, 191, 10.1038/nri2036 Saudemont, 2009, p110gamma and p110delta isoforms of phosphoinositide 3-kinase differentially regulate natural killer cell migration in health and disease, Proc. Natl. Acad. Sci., 106, 5795, 10.1073/pnas.0808594106 Seeliger, 2010, Ligand docking and binding site analysis with PyMOL and Autodock/Vina, J. Comp. Aided. Mol. Des., 24, 417, 10.1007/s10822-010-9352-6 Sérgio, 2006, Protein–ligand docking: current status and future challenges, Proteins Struct. Funct. Bioinf., 65, 15, 10.1002/prot.21082 Sun, 2015, Discovery of a series of novel phenylpiperazine derivatives as EGFR TK inhibitors, Sci. Rep., 5, 1 Tripos International, 2012 Trott, 2010, AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading, J. Comp. Chem., 31, 455 Wennan, 2017, Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy, Acta Pharm. Sinica B, 7, 27, 10.1016/j.apsb.2016.07.006 Xuan-Yu, 2011, Molecular docking: a powerful approach for structure-based drug discovery, Curr. Comput. Aided. Drug. Des., 7, 146, 10.2174/157340911795677602